Riskpilot← Back to searchSign inGet full accessLIER NAPRAPATKLINIKK AS
ASActiveOrg 995488019Bruveien 9, 3403 LierTraditional, complementary and alternative medicine activities · NACE 8696Est. 20102 employees
Revenue 2024
NOK 2,8M
-1% vs 2023
EBITDA margin
10.2%
-49% vs 2023
Equity ratio
37.5%
Financial strength
Net profit 2024
NOK 141K
-61% vs 2023
| Revenue | NOK 2,8M | -1% |
| EBITDA | NOK 281K | -49% |
| Net profit | NOK 141K | -61% |
| Total assets | NOK 1,4M | +3% |
| Equity | NOK 536K | +3% |
| Employees | 2 | — |
Legal name
LIER NAPRAPATKLINIKK AS
Org number
995488019
Legal form
Aksjeselskap
NACE code
8696 · Traditional, complementary and alternative medicine activities
Founded
6. mai 2010
Share capital
NOK 100 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Manuell medisinbehandling med bakgrunn i naprapati og alt som står i forbindelse med dette - herunder å delta i andre selskaper.
Address
Bruveien 9, 3403 Lier
Phone
+4732840800
Email
frode@naprapatlandslaget.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 935 | 1 948 | 2 342 | 1 967 | 2 117 | 2 274 | 2 312 | 2 385 | 2 295 | 2 398 | 2 389 | 2 506 | 2 363 | 2 803 | 2 767 |
| Staff expenses | −870 | −886 | −1 193 | −960 | −1 059 | −1 261 | −1 373 | −1 360 | −1 407 | −1 408 | −1 390 | −1 512 | −1 518 | −1 639 | −1 744 |
| EBITDA | 342 | 93 | 327 | 247 | 237 | 132 | 211 | 447 | 320 | 455 | 465 | 478 | 287 | 552 | 281 |
| Depreciation & amort. | −4 | −12 | −55 | −55 | −56 | −58 | −67 | −67 | −66 | −55 | −55 | −48 | −53 | −56 | −62 |
| EBIT | 339 | 81 | 272 | 192 | 181 | 74 | 144 | 380 | 255 | 400 | 410 | 430 | 233 | 496 | 219 |
| Net financials | 2 | 0 | −62 | −74 | −68 | −60 | −54 | −51 | −47 | −46 | −32 | −27 | −30 | −38 | −38 |
| Profit before tax | 341 | 81 | 209 | 118 | 114 | 14 | 90 | 329 | 208 | 354 | 379 | 403 | 203 | 458 | 181 |
| Tax | 95 | 27 | 62 | 33 | 31 | 2 | 23 | 82 | 51 | 83 | 84 | 89 | 45 | 101 | 40 |
| Net profit | 245 | 54 | 148 | 86 | 83 | 12 | 67 | 247 | 157 | 271 | 295 | 314 | 159 | 357 | 141 |
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 789 | 627 | 1 813 | 1 815 | 1 874 | 1 780 | 1 630 | 1 584 | 1 462 | 1 555 | 1 486 | 1 400 | 1 362 | 1 385 | 1 429 |
| Equity | 345 | 399 | 447 | 532 | 616 | 517 | 434 | 451 | 414 | 470 | 440 | 454 | 463 | 520 | 536 |
| Long-term debt | 0 | 1 | 1 116 | 1 064 | 1 011 | 953 | 900 | 841 | 782 | 724 | 678 | 618 | 557 | 496 | 436 |
| Short-term debt | 442 | 227 | 250 | 219 | 247 | 310 | 296 | 292 | 266 | 361 | 368 | 328 | 343 | 370 | 457 |
| Total debt | 443 | 228 | 1 366 | 1 283 | 1 258 | 1 263 | 1 196 | 1 133 | 1 048 | 1 085 | 1 046 | 946 | 900 | 865 | 894 |
EBITDA margin
10.2%
This company
15.8%
Market median
-35% vs market
20102024
Equity ratio
37.5%
This company
38.2%
Market median
+2% vs market
20102024
Return on equity
26.2%
This company
18.4%
Market median
+42% vs market
20102024
Net profit margin
5.1%
This company
8.1%
Market median
-37% vs market
20102024
Asset turnover
1.94×
This company
1.12×
Market median
+73% vs market
20102024
Debt / equity
1.67×
This company
0.62×
Market median
-169% vs market
20102024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ES Deputy Member | Deputy Member | 2010 | — | — |
EB Deputy Member | Deputy Member | 2010 | — | — |
FH Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2010 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50.0% | 50.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LIER NAPRAPATKLINIKK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erling Sæterøy Boldvik | Deputy Member | 0 companies |
| Erling Boldvik | Deputy Member | 0 companies |
| Frode Hennum | Chief Executive Officer | 0 companies |
| Melinda Jane Williams Hennum | Board of Directors | 0 companies |